Its compounded semaglutide product was never the be-all and end-all for Hims & Hers ... This means that FDA does not review these drugs to evaluate their safety, effectiveness, or quality before ...

Shares of the health and wellness platform operator skyrocketed more than 670% between Jan. 1, 2024, and Feb. 19, 2025. However, this sizzling momentum came to a screeching halt in recent weeks. Hims ...

It has expanded its offerings to include weight loss, focusing on prescription medications, including its own compounded semaglutide ... But some recent Hims and Hers reviews complain about ...

Many treatments are available, and with the popularity of online and mail-order services in recent years, two leaders are BlueChew and Hims. Both companies offer different ED treatments and a ...

The company says its semaglutide injections are fulfilled and shipped from Hims & Hers' affiliated pharmacies ... legal and regulatory (MLR) reviews. In a new pharmaphorum podcast, web editor ...

Hims & Hers had previously offered compounded versions of semaglutide -- the GLP-1 drug marketed as Ozempic and Wegovy -- which it and other compounding pharmacies were allowed to do legally ...

Hims & Hers stock has slumped 40% since the U.S. FDA on February 21 removed Novo Nordisk's top-selling Wegovy and diabetes drug Ozempic, both known chemically as semaglutide, from its shortage list.

Learn More » Much of the excitement over Hims & Hers has been connected to the company's sales of compounded versions of GLP-1 inhibitor semaglutide. Novo Nordisk markets semaglutide as a ...